Literature DB >> 16995868

Two cases of thiopurine methyltransferase (TPMT) deficiency--a lucky save and a near miss with azathioprine.

Sharon J Gardiner1, Richard B Gearry, Murray L Barclay, Evan J Begg.   

Abstract

BACKGROUND: The association between thiopurine methyltransferase (TPMT) deficiency and myelosuppression with azathioprine is well recognized. Two cases are presented that illustrate the very different outcomes that may occur with azathioprine in patients with TPMT deficiency, which affects 0.3-0.6% of caucasians. CASE 1: The first patient's TPMT deficiency was identified following hospitalization for pancytopenia attributed to azathioprine. CASE 2: The second patient was identified as deficient early in treatment and myelosuppression was avoided by treating with a greatly decreased dose (25 mg per week).
CONCLUSIONS: Testing for TPMT ideally should be performed in every patient commencing a thiopurine drug.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16995868      PMCID: PMC1885160          DOI: 10.1111/j.1365-2125.2005.02474.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  22 in total

1.  Safe treatment of thiopurine S-methyltransferase deficient Crohn's disease patients with azathioprine.

Authors:  B A Kaskas; E Louis; U Hindorf; E Schaeffeler; J Deflandre; F Graepler; K Schmiegelow; M Gregor; U M Zanger; M Eichelbaum; M Schwab
Journal:  Gut       Date:  2003-01       Impact factor: 23.059

2.  Practical pharmacogenetics: the cost effectiveness of screening for thiopurine s-methyltransferase polymorphisms in patients with rheumatological conditions treated with azathioprine.

Authors:  Carlo A Marra; John M Esdaile; Aslam H Anis
Journal:  J Rheumatol       Date:  2002-12       Impact factor: 4.666

3.  Thiopurine methyltransferase and 6-thioguanine nucleotide measurement: early experience of use in clinical practice.

Authors:  R B Gearry; M L Barclay; R L Roberts; J Harraway; M Zhang; L S Pike; P M George; C M Florkowski
Journal:  Intern Med J       Date:  2005-10       Impact factor: 2.048

4.  Clinical use and practical application of TPMT enzyme and 6-mercaptopurine metabolite monitoring in IBD.

Authors:  Ernest G Seidman
Journal:  Rev Gastroenterol Disord       Date:  2003

5.  Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease.

Authors:  M C Dubinsky; S Lamothe; H Y Yang; S R Targan; D Sinnett; Y Théorêt; E G Seidman
Journal:  Gastroenterology       Date:  2000-04       Impact factor: 22.682

6.  Mistaken identity: misclassification of TPMT phenotype following blood transfusion.

Authors:  Seau-Tak Cheung; Robert N Allan
Journal:  Eur J Gastroenterol Hepatol       Date:  2003-11       Impact factor: 2.566

7.  Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants.

Authors:  Elke Schaeffeler; Christine Fischer; Dierk Brockmeier; Dorothee Wernet; Klaus Moerike; Michel Eichelbaum; Ulrich M Zanger; Matthias Schwab
Journal:  Pharmacogenetics       Date:  2004-07

8.  TPMT in the treatment of Crohn's disease with azathioprine.

Authors:  L Lennard
Journal:  Gut       Date:  2002-08       Impact factor: 23.059

9.  Methylated metabolites of 6-mercaptopurine are associated with hepatotoxicity.

Authors:  Ulrikka Nygaard; Nina Toft; Kjeld Schmiegelow
Journal:  Clin Pharmacol Ther       Date:  2004-04       Impact factor: 6.875

10.  Pharmacokinetics of 6-mercaptopurine in patients with inflammatory bowel disease: implications for therapy.

Authors:  Luc J J Derijks; Lennard P L Gilissen; Leopold G J B Engels; Laurens P Bos; Paul J Bus; Joseph J H M Lohman; Wouter L Curvers; Sander J H Van Deventer; Daniel W Hommes; Piet M Hooymans
Journal:  Ther Drug Monit       Date:  2004-06       Impact factor: 3.681

View more
  4 in total

1.  Modeling the Outcome of Systematic TPMT Genotyping or Phenotyping Before Azathioprine Prescription: A Cost-Effectiveness Analysis.

Authors:  Kevin Zarca; Isabelle Durand-Zaleski; Marie-Anne Loriot; Gilles Chatellier; Nicolas Pallet
Journal:  Mol Diagn Ther       Date:  2019-06       Impact factor: 4.074

2.  Pharmacoeconomic analyses of azathioprine, methotrexate and prospective pharmacogenetic testing for the management of inflammatory bowel disease.

Authors:  Virginia L Priest; Evan J Begg; Sharon J Gardiner; Christopher M A Frampton; Richard B Gearry; Murray L Barclay; David W J Clark; Paul Hansen
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

3.  Implementation of TPMT testing.

Authors:  Lynne Lennard
Journal:  Br J Clin Pharmacol       Date:  2014-04       Impact factor: 4.335

4.  Thiopurine S-methyltransferase activity in Nigerians: phenotypes and activity reference values.

Authors:  Ayorinde Adehin; Oluseye O Bolaji
Journal:  BMC Res Notes       Date:  2018-02-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.